Business
ADMA is a U.S.-based commercial biopharmaceutical company that manufactures, markets, and develops specialty biologics for immunodeficient patients and others at risk for infectious diseases.
ADMA grew revenue and margins, but net income and free cash flow fell while the Beneish screen flagged.
The read at a glance✓ Audited against SEC data
- Business mix — End-to-end specialty biologics manufacturerNote
- Revenue — Revenue +19.6% to $510MOK
- Profitability — Net income -25.7% to $146.9MWatch
- Cash quality — Free cash flow -74.8% to $27.8MWatch
- Margins — Gross and operating margins improvedOK
- Insiders — 2 buys / 9 sells; $217K boughtNote
- Accounting — Beneish-M flag; EQ greyWatch
Where the revenue comes from
Fiscal 2025, as ADMA BIOLOGICS, INC. reports it. History and quarterly detail are in the app.
- ADMA Bio Manufacturing$493.1M
- Plasma Collection Centers$17.0M
Leadership changes
From ADMA BIOLOGICS, INC.'s own filings, the day they're filed.
- Eduardo Rene Salas · director · appointmenteff. 2024-12-30
- Young T. Kwon · Chairman · appointmenteff. 2024-11-19
- Bryant E. Fong · Directors · departureeff. 2024-11-19
Latest filings
- 8-K · Company announcement2026-08-05
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-06-02
- 8-K · Company announcement2026-05-06
- 10-Q · Quarterly report2026-05-06
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about ADMA BIOLOGICS, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.